secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-168273
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF
----------------------------------------------------------------------------

- Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).
- Trial enriches for patients with PVR >3 on right heart catheterization; ~180 subjects expected.
- Subjects randomized 1:1:1 to two TX45 doses or placebo; 24-week treatment plus 8-week follow-up.
- Goal: evaluate efficacy in combined pre- and post-capillary PH and whole Group 2 PH-HFpEF population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/0001193125-24-168273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/d822923d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-168273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer